Bartomeu Massutí

20.5k total citations · 1 hit paper
199 papers, 6.5k citations indexed

About

Bartomeu Massutí is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bartomeu Massutí has authored 199 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pulmonary and Respiratory Medicine, 138 papers in Oncology and 41 papers in Molecular Biology. Recurrent topics in Bartomeu Massutí's work include Lung Cancer Treatments and Mutations (104 papers), Colorectal Cancer Treatments and Studies (56 papers) and Lung Cancer Diagnosis and Treatment (49 papers). Bartomeu Massutí is often cited by papers focused on Lung Cancer Treatments and Mutations (104 papers), Colorectal Cancer Treatments and Studies (56 papers) and Lung Cancer Diagnosis and Treatment (49 papers). Bartomeu Massutí collaborates with scholars based in Spain, United States and France. Bartomeu Massutí's co-authors include Rafael Rosell, Manuel Cobo, Carlos Camps, Vicente Alberola, Dolores Isla, José Javier Sánchez, Enriqueta Felip, Miquel Tarón, Alfredo Carrato and Teresa Morán and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Bartomeu Massutí

189 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

2022 296 citations Byoung Chul Cho, Delvys Rodríguez‐Abreu et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Bartomeu Massutí

Since Specialization

Citations

This map shows the geographic impact of Bartomeu Massutí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bartomeu Massutí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bartomeu Massutí more than expected).

Fields of papers citing papers by Bartomeu Massutí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bartomeu Massutí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bartomeu Massutí. The network helps show where Bartomeu Massutí may publish in the future.

Co-authorship network of co-authors of Bartomeu Massutí

This figure shows the co-authorship network connecting the top 25 collaborators of Bartomeu Massutí. A scholar is included among the top collaborators of Bartomeu Massutí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bartomeu Massutí. Bartomeu Massutí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) 2025 ·OncoImmunology ·(unknown), (unknown), Ernest Nadal, (unknown), (unknown), (unknown), Bartomeu Massutí, Aránzazu García‐Grande, (unknown), Amelia Insa, Javier de Castro, (unknown), Margarita Majem, Alex Martínez‐Martí, Diego Megı́as, (unknown), Ana Collazo-Lorduy, Virginia Calvo, Mariano Provencio, Alberto Cruz‐Bermúdez	0
2	Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma 2025 ·Lung Cancer ·Ernest Nadal, Paloma Martín-Martorell, José Carlos Benítez, María Ángeles Sala, S. Cedrés, Carlos Álvarez-Fernández, Manuel Dómine, (unknown), Maria Saigí, Rafael López Castro, Laia Vilà, Bartomeu Massutí, (unknown), (unknown), Amelia Insa, (unknown), (unknown), Cristina Muñoz‐Pinedo, (unknown), Mariano Provencio	0
3	Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. 2024 ·Journal of Clinical Oncology ·Natasha B. Leighl, Hiroaki Akamatsu, (unknown), Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, (unknown), (unknown), Ali Alhadab, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro	12
4	Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial 2023 ·British Journal of Cancer ·Sophie Postel‐Vinay, (unknown), Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, R. de las Peñas, (unknown), Santiago Viteri, (unknown), Ana Laura Ortega Granados, Teresa Morán, Carlos Camps, Ana López, Mariano Provencio, Jean‐Charles Soria, Benjamin Besse, Bartomeu Massutí, Rafael Rosell	4
5	Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer 2023 ·JCO Clinical Cancer Informatics ·(unknown), María Torrente, Luca Costabello, Virginia Calvo, Brian H. Walsh, Carlos Camps, Sameh K. Mohamed, Ana Laura Ortega Granados, Vít Nováček, Bartomeu Massutí, Pasquale Minervini, (unknown), E. del Barco, Joaquim Bosch‐Barrera, Ernestina Menasalvas, Mohan Timilsina, Mariano Provencio	11
6	Difficulties on the access to innovative targeted therapies for lung cancer in Spain 2023 ·Clinical & Translational Oncology ·Virginia Calvo, Carlos Camps, Enric Carcereny, Manuel Cobo, Manuel Dómine, M.R. García Campelo, J.L. González-Larriba, M. Guirado, Florentino Hernándo, Bartomeu Massutí, Ernest Nadal, Delvys Rodríguez‐Abreu, (unknown), Ivana Sullivan, Mariano Provencio, (unknown)	3
7	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study breakdown → 2022 ·The Lancet Oncology ·Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Ki Hyeong Lee, Bartomeu Massutí, Sandrine Hiret, (unknown), Fabrice Barlési, Dae Ho Lee, Luis Paz Ares, Robert W. Hsieh, Namrata S. Patil, Patrick J. Twomey, Xiaoying Yang, Raymond D. Meng, Melissa L. Johnson	296
8	Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study 2021 ·Cancers ·Elisa Conde, Julie Earl, (unknown), (unknown), (unknown), (unknown), José Carlos Martínez Ávila, (unknown), (unknown), (unknown), Mercedes Rodríguez-Garrote, Bruno Sáinz, Bartomeu Massutí, Pilar García‐Alfonso, Manuel Benavides, Enrique Aranda, Laura García‐Bermejo, Alfredo Carrato	11
9	Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database 2020 ·Thoracic Cancer ·Begoña Campos, Javier de Castro, Bartomeu Massutí, (unknown), (unknown), (unknown), (unknown), Manuel Cobo	26
10	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) 2019 ·Translational Lung Cancer Research ·Mariano Provencio, Enric Carcereny, Delvys Rodríguez‐Abreu, Rafael López Castro, M. Guirado, Carlos Camps, Joaquim Bosch‐Barrera, Rosario García‐Campelo, Ana Laura Ortega Granados, J.L. González-Larriba, Joaquín Casal‐Rubio, Manuel Dómine, Bartomeu Massutí, María Ángeles Sala, Reyes Bernabé, Juana Oramás, E. del Barco	43
11	The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial 2014 ·Clinical Cancer Research ·Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez‐Capitán, Jordi Bertrán-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massutí, Jia Wei, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García‐Campelo, Santiago Viteri, Miquel Tarón, Mayumi Ono, Petros Giannikopoulos, Trever G. Bivona, Rafael Rosell	180
12	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer 2014 ·Clinical Cancer Research ·Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó, Clara Mayo‐de‐las‐Casas, (unknown), (unknown), Laura Bonanno, Adolfo Favaretto, Andrés F. Cardona, A. Vergnenègre, Margarita Majem, Bartomeu Massutí, Teresa Morán, Enric Carcereny, Santiago Viteri, Rafael Rosell	125
13	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study 2014 ·Annals of Oncology ·Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, (unknown), Simon Hitier, P. Rougier	88
14	Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab 2013 ·Clinical Colorectal Cancer ·Javier Sastre, Marta Vidaurreta, (unknown), Fernando Rivera, Bartomeu Massutí, (unknown), Albert Abad, Manuel Gallén, Manuel Benavides, Enrique Aranda, Eduardo Díaz‐Rubio	30
15	Biomarkers in lung oncology 2010 ·Pulmonary Pharmacology & Therapeutics ·Rafael Rosell, A. Vergnenègre, Baorui Liu, Manuel Cobo, Bartomeu Massutí, Jia Wei, Miguel Ángel Molina‐Vila, Carlota Costa, Cristina Queralt, Miquel Tarón	14
16	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung 2008 ·Clinical Cancer Research ·Marcin Skrzypski, Ewa Jassem, Miquel Tarón, José Javier Sánchez, Pedro Méndez, Witold Rzyman, (unknown), Dan J. Raz, David M. Jablons, Mariano Provencio, Bartomeu Massutí, Imane Chaib, Laia Perez‐Roca, Jacek Jassem, Rafael Rosell	84
17	P3-082: Erlotinib as third and successive line of treatment in advanced or metastatic non-small cell lung cancer patients 2007 ·Journal of Thoracic Oncology ·A. García, R. Pérez-Carrión, Javier de Castro, Pilar Garrido, (unknown), J.L. González-Larriba, (unknown), Mariano Provencio, (unknown), Bartomeu Massutí	1
18	C3-02: Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Mature results of the SLCG 0008 study 2007 ·Journal of Thoracic Oncology ·Pilar Garrido, (unknown), Bartomeu Massutí, Jordi Andreu, Óscar Juan, (unknown), F. Cardenal, (unknown), (unknown), Rafael Rosell	5
19	Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation 1999 ·European Respiratory Journal ·Conchita Martín, (unknown), José Sánchez–Payá, Bartomeu Massutí, J.M. Arriero, L. A. Hernandez	63
20	Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer 1997 ·Lung Cancer ·Alfredo Carrato, Rafael Rosell, Carlos Camps, Antonio Antón, Ramón García-Gómez, Enrique Aranda, Bartomeu Massutí, (unknown), (unknown), (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact